Evidence map›Paper›PMID 42646448›Full record

ArticleNanomaterials (Basel, Switzerland)2026

Dose-Response Relationships for Lung Tumor and Pleural Mesothelioma Induction by Repetitive Intratracheal Instillation of a Multiwalled Carbon Nanotube, MWCNT-7, in Rats: Comparison with Inhalation Carcinogenicity Based on Lung Burden.

Ai Maeno, Motoki Hojo, Yoshimitsu Sakamoto, Yukio Yamamoto, Kiyomi Ikushima, Kai Igarashi, Satoshi Yokota, Yuhji Taquahashi, Norihiro Kobayashi, Hiroyuki Tsuda and 7 more

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ai MaenoDepartment of Pharmaceutical and Environment Health, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku-Ku, Tokyo 169-0073, Japan.
Motoki HojoDepartment of Pharmaceutical and Environment Health, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku-Ku, Tokyo 169-0073, Japan.ORCID 0000-0001-5386-5110
Yoshimitsu SakamotoDepartment of Pharmaceutical and Environment Health, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku-Ku, Tokyo 169-0073, Japan.
Yukio YamamotoDepartment of Pharmaceutical and Environment Health, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku-Ku, Tokyo 169-0073, Japan.
Kiyomi IkushimaDepartment of Pharmaceutical and Environment Health, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku-Ku, Tokyo 169-0073, Japan.
Kai IgarashiDepartment of Pharmaceutical and Environment Health, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku-Ku, Tokyo 169-0073, Japan.
Satoshi YokotaDivision of Cellular and Molecular Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26 Tono-Machi, Kawasaki-Ku, Kawasaki 210-9501, Japan.ORCID 0000-0002-7660-6303
Yuhji TaquahashiDivision of Cellular and Molecular Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26 Tono-Machi, Kawasaki-Ku, Kawasaki 210-9501, Japan.ORCID 0000-0002-4612-0652
Norihiro KobayashiDivision of Environmental Chemistry, National Institute of Health Sciences, 3-25-26 Tono-Machi, Kawasaki-Ku, Kawasaki 210-9501, Japan.ORCID 0000-0002-4556-2598
Hiroyuki TsudaNanotoxicology Project, Graduate School of Medical Sciences, Nagoya City University, 1 Aza Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya 467-8601, Japan.
Aya Naiki-ItoDepartment of Experimental Pathology and Tumor Biology, Graduate School of Medical Sciences, Nagoya City University, 1 Aza Kawasumi, Mizuho-Cho, Mizuho-Ku, Nagoya 467-8601, Japan.ORCID 0000-0003-0828-2033
Takamasa NumanoNational Institute of Occupational Safety and Health, Japan Organization of Occupational Health and Safety, 2-26-1 Muraokahigashi, Fujisawa 251-0012, Japan.
Jun KannoDivision of Cellular and Molecular Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences, 3-25-26 Tono-Machi, Kawasaki-Ku, Kawasaki 210-9501, Japan.
Akihiko HiroseChemicals Assessment and Research Center, Chemicals Evaluation and Research Institute, Japan, 1-4-25 Koraku, Bunkyo-Ku, Tokyo 112-0004, Japan.ORCID 0000-0003-1703-4883
Akiko InomataDepartment of Pharmaceutical and Environment Health, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku-Ku, Tokyo 169-0073, Japan.ORCID 0000-0001-7111-4791
Junichi KamiieLaboratory of Veterinary Pathology, Graduate School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-Ku, Sagamihara 252-0206, Japan.ORCID 0000-0003-0228-9007
Dai NakaeDepartment of Medical Sports, Faculty of Health Care and Medical Sports, Teikyo Heisei University, 4-1 Uruido-Minami, Ichihara 290-0193, Japan.ORCID 0000-0001-5895-3830

Funding

Ministry of Health Labour and Welfare 21KD2004
6 · The paper itself

Abstract

The multiwalled carbon nanotube, MWCNT-7, is carcinogenic to rat lungs when inhaled over the course of 2 years, but does not induce pleural mesothelioma. In contrast, intratracheal instillation of MWCNT-7 causes both lung tumors and pleural mesotheliomas. To explore the possibility of the use of the intratracheal instillation technique in risk characterization, we administered this widely used reference material using instillation to male F344 rats at doses of 0.0175, 0.07, 0.28, or 0.42 mg/kg once per week for 13 weeks, followed by an observation period of 91 weeks and compared the dose-response toxicological data with the 2-year inhalation study. Lung tumors and pleural mesotheliomas were induced in a dose-dependent manner (the 0.42 mg/kg group was excluded from analysis of lung tumor formation). The lung burden of MWCNT-7 at week 13 was dose-dependent: 0.0302, 0.191, 0.98, and 1.369 mg/lung in the 0.0175, 0.07, 0.28, and 0.42 mg/kg groups, respectively. The number of fibers in the pleural lavage fluid was also dose-dependent. The no-observed-adverse-effect-level (NOAEL) of MWCNT-7's carcinogenicity was 0.0302 mg/lung based on no significant lung tumor induction and no mesothelioma induction in the 0.0175 mg/kg group. When compared based on lung burden, the dose-response relationship and NOAEL of lung tumor induction resembled those in the 2-year inhalation study, offering the possibility of the application of this protocol for risk characterization.

Indexed as

carcinogenicitydose–response relationshipintratracheal instillationlung burdenlung tumorsMWCNTNOAELpleural mesothelioma

Identifiers

PMID42646448
PMCPMC13515796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.